Edgewise Corp (EWTX) - Long-Term Debt to Capital Coefficient

Edgewise Therapeutics (EWTX) generates revenue through grants and investments while developing innovative treatments for severe muscle pathologies. The company is currently in the clinical testing stage, where operational expansion is driving increased laboratory expenditures. Meanwhile, streamlined supply chains and strict temperature controls ensure high profitability. This daily price chart for the stock with the 0.01 metric clearly demonstrates the financial standing of this biopharmaceutical business.

For the biopharmaceutical business of Edgewise Therapeutics (EWTX), which faces high clinical trial costs, the long-term debt-to-equity ratio serves as an indicator of financial viability. This metric is calculated as the ratio of liabilities with a maturity exceeding one year to shareholders' equity, allowing investors to assess the company's reliance on borrowed funds while building future high-margin profits.